CN113652428B - 核膜蛋白敲降在干细胞移植方面的应用 - Google Patents
核膜蛋白敲降在干细胞移植方面的应用 Download PDFInfo
- Publication number
- CN113652428B CN113652428B CN202110972070.3A CN202110972070A CN113652428B CN 113652428 B CN113652428 B CN 113652428B CN 202110972070 A CN202110972070 A CN 202110972070A CN 113652428 B CN113652428 B CN 113652428B
- Authority
- CN
- China
- Prior art keywords
- seq
- neural stem
- stem cells
- nuclear membrane
- membrane protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种核膜蛋白敲降在干细胞移植方面的应用,具体包括步骤1)、在线设计2对针对核膜蛋白的siRNA引物,构建慢病毒载体;步骤2)、体外慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预;步骤3)、体内慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预。本发明将LBR(核膜蛋白)用于抑制干细胞的分裂,促进干细胞的分化;神经干细胞移植后会可能存在较强的分裂能力,存在潜在致癌性。核膜蛋白敲降后,细胞分裂能力显著降低,因此该方法可广泛用于干细胞移植带来的致癌性问题。
Description
技术领域
本发明涉及核膜蛋白敲降在干细胞移植方面的应用,属于干细胞移植领域。
背景技术
干细胞移植已成为再生领域的重要议题,然而其存在明显的致癌风险。常见的手段包括(i)化学治疗,(ii)基因治疗,和(iii)免疫治疗。免疫治疗存在高成本、批次之间的差异、非特异性抗体结合,和副作用大等缺陷。化学小分子的治疗则效率相对低下,目前难以满足临床的需求。基因治疗通常针对重编程转录因子,然而对重编程因子进行改造,容易导致细胞状态发生严重损害,不利于干细胞分化。
中枢神经系统损伤后,除原发性机械损伤直接造成的神经元死亡外,继发性损伤也会导致神经元持续性的凋亡、坏死,由此出现不同程度的轴突缺失及功能障碍。另一方面,成年哺乳动物的脊髓区域干细胞数量有限,且损伤后主要向胶质细胞而非神经元转化。因此,在哺乳动物受损区域补充新生神经元及修复上下行神经通路,对神经损伤修复具有重要意义。常见的方法是外源干细胞的移植使其在体内分化为神经元。但神经干细胞的增殖能力较强,存在严重的致癌风险,目前对其调控手段仍极为有限。
发明内容
本发明提供了一种核膜蛋白敲降在干细胞移植方面的应用,将LBR(核膜蛋白)用于抑制干细胞分裂,促进其分化,可广泛用于干细胞移植带来的致癌性问题。
本发明为解决上述技术问题采用以下技术方案:
一种核膜蛋白敲降在干细胞移植方面的应用,包括以下步骤:
步骤1)、在线设计2对针对核膜蛋白的siRNA引物,引物序列如SEQ ID No.1和SEQID No.2所示,构建慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2;
步骤2)、体外慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预;
21)神经干细胞的获取及传代:取分离的大鼠神经干细胞在培养基中进行传代,原代培养物生长5天,神经干细胞每4天传代一次,取第2-4代的神经干细胞用于所有实验;
22)取步骤1)所构建的慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2,其MOI=10,分别对步骤21)获取的第2-4代的神经干细胞进行转染;12小时后加入500μl完全培养基;病毒转染后72小时,检测神经干细胞中的GFP表达以确定病毒滴度;
步骤3)、体内慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预;
31)在小鼠脊髓损伤后1-2周分别注射步骤22)经病毒转染后的神经干细胞10万-100万个;
32)在神经干细胞体内移植后的2-8周内,利用慢病毒介导的核膜蛋白敲降,即通过微量注射泵进行慢病毒载体的注射,注射浓度为106-108/μL,注射体积为0.5μL-4μL;
33)损伤后6周对小鼠灌流固定,取相应脊髓节段,30μm连续切片,每个样品随机取3张切片进行免疫组化,对神经干细胞的分裂分化进行鉴定。
进一步的,所述步骤1)包括以下步骤:
11)、在线设计2对针对核膜蛋白的siRNA引物,引物序列如SEQ ID No.1和SEQ IDNo.2所示,并合成相关引物;
12)、正反义寡核苷酸链退火;按以下体系配制退火反应体系:
1ug/μl正义寡核苷酸链5μl;
1ug/μl反义寡核苷酸链5μl;
ddH2O 15μl;
反应条件:95℃,反应5分钟,后缓慢降至室温,得到退火后的寡核苷酸双链;
其中,lbr-shRNAi-1的正义寡核苷酸链如SEQ ID No.3所示;对应的反义寡核苷酸链SEQ ID No.4所示;
lbr-shRNAi-2的正义寡核苷酸链如SEQ ID No.5所示;对应的反义寡核苷酸链SEQID No.6所示;
13)、用AgeI和EcoRI双酶切线性化质粒GV112,得到改造后的线性化载体;酶切体系是:
反应条件:37度3小时
14)、连接步骤12)退火形成的寡核苷酸双链与步骤13)所得改造后的线性化载体,得到重组质粒;按照以下体系配制连接反应体系:
反应条件:4℃过夜;
15)、转化及鉴定
将步骤14)连接所得的重组质粒导入感受态的大肠杆菌体内,以从含有抗生素的LB平板上挑取单菌落,进行测序;
16)、将上述连接重组的质粒和包装辅助质粒pHelper 1.0及pHelper 2.0,转染到293T细胞中产生复制缺陷型慢病毒;收集上清液,并离心浓缩,纯化得到慢病毒载体;通过测量共表达的GFP确定病毒滴度。
进一步的,所述步骤15)中鉴定包括以下步骤:
151)配制如下反应体系,震荡混匀,短暂离心;
ddH2O 9.2ul
2×Taq Plus Master Mix 10ul
上游引物:10μM,0.4ul;序列如SEQ ID No.7所示;
下游引物:10μM,0.4ul;序列如SEQ ID No.8所示;
单菌落–
PCR反应条件:94℃,3min;94℃30s,55℃30s,72℃30s共22cycles;72℃3min;4℃∞;
152)在超净工作台中,用无菌的枪头挑单个菌落至20μL至鉴定体系中,吹打混匀,置于PCR仪中进行反应,反应体系共20ul;
153)将鉴定出的阳性克隆转化子接种于适量含相应抗生素的LB液体培养基中,37℃培养12-16h,取适量菌液进行测序,测序引物如SEQ ID No.8所示;若测序结果含SEQ IDNo.1和SEQ ID No.2则成功。
进一步的,所述步骤21)中培养基包括:DMEM/F12、1X B27、1X PS、20ng/mL EGF和20ng/mL bFGF。
进一步的,所述步骤22)中完全培养基包括:DMEM/F12、1X B27、1XPS、50ng/ml EGF和50ng/ml bFGF。
有益效果
目前已知的方法效率较低,本发明可在抑制分裂及促进分化中起到双重作用,而且效果非常显著。
1.可促进神经干细胞的分化。该方法有助于神经元的形成,以此改善神经系统疾病,如阿尔兹海默症及脊髓损伤的修复等。
2.可抑制干细胞的致癌性。神经干细胞移植后会可能存在较强的分裂能力,存在潜在致癌性。LBR敲降后,细胞分裂能力显著降低。
附图说明
图1为通过慢病毒携带的LBR shRNA敲降在神经干细胞移植中抑制其致瘤性的示意图;
图2为Western blot验证慢病毒携带的LBR shRNA的敲降效果示意图;
图3为本发明实施例中LBR敲降后,神经干细胞分化形成神经元的示意图;其中图3A为转染对照组的shRNA(scrambled RNA);其中图3B右侧转染LBR的shRNA;
图4为本发明实施例中神经干细胞转染LBR shRNA后,神经干细胞分化为神经元(β-III tubulin)的示意图;
图5为CCK8显示LBR敲降后不同靶点的细胞增殖能力变化示意图。
具体实施方式
下面详细描述本发明的实施方式,所述实施方式的示例在附图中示出。下面通过参考附图描述的实施方式是示例性的,仅用于解释本发明,而不能解释为对本发明的限制。
本发明为解决上述技术问题采用以下技术方案:
一种核膜蛋白敲降在干细胞移植方面的应用,包括以下步骤:
步骤1)、在线设计2对针对核膜蛋白的siRNA引物,构建慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2;
11)、在线设计2对针对核膜蛋白的siRNA引物,序列分别为SEQ ID No.1:CAGCTTTACACTGTGAAGTAT和SEQ ID No.2:CACCAGAGGACCTGTACCTTT,并合成相关引物;
12)、正反义寡核苷酸链退火;按以下体系配制退火反应体系:
1ug/μl正义寡核苷酸链5μl;
1ug/μl反义寡核苷酸链5μl;
ddH2O 15μl;
反应条件:用移液器轻轻吹打混匀,短暂离心,放入PCR仪中,95℃,反应5分钟,后缓慢降至室温,得到退火后的寡核苷酸双链;
其中,lbr-shRNAi-1的正义寡核苷酸链如SEQ ID No.3所示;对应的反义寡核苷酸链SEQ ID No.4所示;
SEQ ID No.3:
ccggCAGCTTTACACTGTGAAGTATctcgagATACTTCACAGTGTAAAGCTGtttttg
SEQ ID No.4:
aattcaaaaaCAGCTTTACACTGTGAAGTATctcgagATACTTCACAGTGTAAAGCTG;
lbr-shRNAi-2的正义寡核苷酸链如SEQ ID No.5所示;对应的反义寡核苷酸链SEQID No.6所示;
SEQ ID No.5:
ccggCACCAGAGGACCTGTACCTTTctcgagAAAGGTACAGGTCCTCTGGTGtttttg
SEQ ID No.6:
aattcaaaaaCACCAGAGGACCTGTACCTTTctcgagAAAGGTACAGGTCCTCTGGTG;
13)、用AgeI和EcoRI双酶切线性化质粒GV112,得到改造后的线性化载体;按列表顺序依次加入各种试剂,用移液器轻轻吹打混匀,短暂离心。
反应条件:37度反应3小时;对载体酶切产物进行琼脂糖凝胶电泳,回收目的条带。
14)、连接步骤12退火形成的寡核苷酸双链与步骤13所得改造后的线性化载体,得到重组质粒;按照以下体系配制连接反应体系:
反应条件:用移液器轻轻吹打混匀,短暂离心4℃过夜;
15)、转化及鉴定
将步骤14)连接所得的重组质粒导入感受态的大肠杆菌体内,以从含有抗生素的LB平板上挑取单菌落,进行测序;
151)配制如下反应体系,震荡混匀,短暂离心;
ddH2O 9.2ul
2×Taq Plus Master Mix 10ul
上游引物:10μM,0.4ul;序列如SEQ ID No.7所示:CCATGATTCCTTCATATTTGC;
下游引物:10μM,0.4ul;序列如SEQ ID No.8所示:GTAATACGGTTATCCACGCG;
单菌落–
PCR反应条件:94℃,3min;94℃30s,55℃30s,72℃30s共22cycles;72℃3min;4℃∞;
152)在超净工作台中,用无菌的枪头挑单个菌落至20μL至鉴定体系中,吹打混匀,置于PCR仪中进行反应,反应体系共20ul;
153)将鉴定出的阳性克隆转化子接种于适量含相应抗生素的LB液体培养基中,37℃培养12-16h,取适量菌液进行测序,测序引物为SEQ ID No.7:CCATGATTCCTTCATATTTGC;若测序结果含SEQ ID No.1:CAGCTTTACACTGTGAAGTAT和SEQ ID No.2:CACCAGAGGACCTGTACCTTT则成功。
16)、将上述连接重组的质粒和包装辅助质粒pHelper 1.0及pHelper 2.0,转染到293T细胞中产生复制缺陷型慢病毒;收集上清液,并离心浓缩,纯化得到慢病毒载体;通过测量共表达的GFP确定病毒滴度。
步骤2)、体外慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预;
21)神经干细胞的获取及传代:一只怀孕大约14天的成年雌性SD大鼠被异氟醚吸入深度麻醉,并通过颈椎溶解术实施安乐死。切除胎鼠的大脑,置于冰冷的PBS中,小心地解剖出大脑皮层。皮层用移液管研磨几分钟,通过40μM过滤器获得单细胞悬液,在培养基中进行传代,培养基为:DMEM/F12(Corning,10-092-CV)、1X B27(Gibco,17504-044)、1X PS(Beyotime,C0222)、20ng/mL EGF(Peprotech,AF-100-15-100)和20ng/mL bFGF(Novus,NBP2-35152)。神经干细胞每4天传代一次,取第2-4代的神经干细胞用于所有实验;
22)取步骤1)所构建的慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2,其MOI=10,分别对步骤21)获取的第2-4代的神经干细胞进行转染;12小时后加入500μl完全培养基;病毒转染后72小时,检测神经干细胞中的GFP表达以确定病毒滴度;完全培养基为DMEM/F12、1XB27、1XPS、50ng/ml EGF和50ng/ml bFGF。
步骤3)、体内慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预,如图1所示;
将小鼠俯卧在保温垫上,麻醉后进行T10椎板摘除术,暴露脊髓。用No.5Dumont镊子(尖端磨成0.5mm的宽度,中间不加垫片)从左右两侧挤压脊髓5秒。术后腹腔注射生理盐水补充体液,每天手工按压膀胱帮助排尿。损伤2天后筛选排除后肢有刺激反应的小鼠,将剩余小鼠随机分成两组,每组6只以上。脊髓损伤后1-2周分别注射步骤22)经病毒转染后的神经干细胞10万-100万个(用5μl微型注射器在损伤部位附近缓缓注入)。神经干细胞转移体内2-8周后,使其在体内环境扩增后进行慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2(108/μl*0.5μl)的注射。损伤后6周对小鼠灌流固定,取相应脊髓节段,30μm连续切片,每个样品随机取3张切片进行免疫组化,对神经干细胞的分裂分化进行鉴定。
如图2所示,采用慢病毒介导的LBR shRNA,LBR的表达量显著下降;
如图3所示,LBR敲降后,神经球消失,取而代之的是分化的细胞形态;
如图4所示,神经干细胞转染LBR shRNA后,神经干细胞可分化为神经元(β-IIItubulin),该方法可促进神经干细胞的分化,因此有助于神经元的形成,以此改善神经系统疾病,如阿尔兹海默症及脊髓损伤的修复等。
如图5所示,神经干细胞移植后会可能存在较强的分裂能力,存在潜在致癌性。LBR敲降后,细胞分裂能力显著降低。
序列表
<110> 南通大学
<120> 核膜蛋白敲降在干细胞移植方面的应用
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
cagctttaca ctgtgaagta t 21
<210> 2
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
caccagagga cctgtacctt t 21
<210> 3
<211> 58
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
ccggcagctt tacactgtga agtatctcga gatacttcac agtgtaaagc tgtttttg 58
<210> 4
<211> 58
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
aattcaaaaa cagctttaca ctgtgaagta tctcgagata cttcacagtg taaagctg 58
<210> 5
<211> 58
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
ccggcaccag aggacctgta cctttctcga gaaaggtaca ggtcctctgg tgtttttg 58
<210> 6
<211> 58
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
aattcaaaaa caccagagga cctgtacctt tctcgagaaa ggtacaggtc ctctggtg 58
<210> 7
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
ccatgattcc ttcatatttg c 21
<210> 8
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gtaatacggt tatccacgcg 20
Claims (4)
1.一种核膜蛋白敲降在体外对神经干细胞增殖分化进行干预的应用,其特征在于,包括以下步骤:
步骤1)、在线设计2对针对核膜蛋白的siRNA,所述siRNA序列如SEQ ID No.1和SEQ IDNo.2所示,构建慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2;
步骤2)、体外慢病毒介导的核膜蛋白敲降对神经干细胞增殖分化进行干预;
21)神经干细胞的获取及传代:取分离的大鼠神经干细胞在培养基中进行传代,原代培养物生长5天,神经干细胞每4天传代一次,取第2-4代的神经干细胞用于所有实验;
22)取步骤1)所构建的慢病毒载体lbr-shRNAi-1和lbr-shRNAi-2,其MOI=10,分别对步骤21)获取的第2-4代的神经干细胞进行转染;12小时后加入500μL完全培养基;病毒转染后72小时,检测神经干细胞中的GFP表达以确定病毒滴度;
所述步骤1)包括以下步骤:
11)、在线设计2对针对核膜蛋白的siRNA,所述siRNA序列如SEQ ID No.1和SEQ IDNo.2所示;
12)、正反义寡核苷酸链退火;按以下体系配制退火反应体系:
1μg/μL正义寡核苷酸链5μL;
1μg/μL反义寡核苷酸链5μL;
ddH2O 15μL;
反应条件:95℃,反应5分钟,后缓慢降至室温,得到退火后的寡核苷酸双链;
其中,lbr-shRNAi-1的正义寡核苷酸链如SEQ ID No.3所示;对应的反义寡核苷酸链SEQ ID No.4所示;
lbr-shRNAi-2的正义寡核苷酸链如SEQ ID No.5所示;对应的反义寡核苷酸链SEQ IDNo.6所示;
13)、用AgeI和EcoRI双酶切线性化质粒GV112,得到改造后的线性化载体;酶切体系是:
反应条件:37度3小时;
14)、连接步骤12)退火形成的寡核苷酸双链与步骤13)所得改造后的线性化载体,得到重组质粒;按照以下体系配制连接反应体系:
反应条件:4℃过夜;
15)、转化及鉴定
将步骤14)连接所得的重组质粒导入感受态的大肠杆菌体内,以从含有抗生素的LB平板上挑取单菌落,进行测序;
16)、将上述连接重组的质粒和包装辅助质粒pHelper 1.0及pHelper 2.0,转染到293T细胞中产生复制缺陷型慢病毒;收集上清液,并离心浓缩,纯化得到慢病毒载体;通过测量共表达的GFP确定病毒滴度。
2.根据权利要求1所述核膜蛋白敲降在体外对神经干细胞增殖分化进行干预的应用,其特征在于,所述步骤15)中鉴定包括以下步骤:
151)配制如下反应体系,震荡混匀,短暂离心;
ddH2O 9.2μL;
2×Taq Plus Master Mix 10μL;
上游引物:10μM,0.4μL;序列如SEQ ID No.7所示;
下游引物:10μM,0.4μL;序列如SEQ ID No.8所示;
152)在超净工作台中,用无菌的枪头挑单个菌落至20μL至鉴定体系中,吹打混匀,置于PCR仪中进行反应,反应体系共20μL;
153)将鉴定出的阳性克隆转化子接种于适量含相应抗生素的LB液体培养基中,37℃培养12-16h,取适量菌液进行测序,测序引物如SEQ ID No.8所示;若测序结果含SEQ ID No.1和SEQ ID No.2则成功。
3.根据权利要求1所述核膜蛋白敲降在体外对神经干细胞增殖分化进行干预的应用,其特征在于,所述步骤21)中培养基包括:DMEM/F12、1X B27、1X PS、20ng/mL EGF和20ng/mLbFGF。
4.根据权利要求1所述核膜蛋白敲降在体外对神经干细胞增殖分化进行干预的应用,其特征在于,所述步骤22)中完全培养基包括:DMEM/F12、1X B27、1XPS、50ng/ml EGF和50ng/ml bFGF。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110972070.3A CN113652428B (zh) | 2021-08-24 | 2021-08-24 | 核膜蛋白敲降在干细胞移植方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110972070.3A CN113652428B (zh) | 2021-08-24 | 2021-08-24 | 核膜蛋白敲降在干细胞移植方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113652428A CN113652428A (zh) | 2021-11-16 |
CN113652428B true CN113652428B (zh) | 2023-09-22 |
Family
ID=78481731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110972070.3A Active CN113652428B (zh) | 2021-08-24 | 2021-08-24 | 核膜蛋白敲降在干细胞移植方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113652428B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103865956A (zh) * | 2013-06-09 | 2014-06-18 | 南通大学 | 利用重组慢病毒诱导神经干细胞向多巴胺能神经元分化的方法 |
CN105200059A (zh) * | 2015-10-22 | 2015-12-30 | 山西医科大学 | 靶向抑制小鼠UCP2基因表达的siRNA及其表达载体的构建 |
-
2021
- 2021-08-24 CN CN202110972070.3A patent/CN113652428B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103865956A (zh) * | 2013-06-09 | 2014-06-18 | 南通大学 | 利用重组慢病毒诱导神经干细胞向多巴胺能神经元分化的方法 |
CN105200059A (zh) * | 2015-10-22 | 2015-12-30 | 山西医科大学 | 靶向抑制小鼠UCP2基因表达的siRNA及其表达载体的构建 |
Non-Patent Citations (1)
Title |
---|
Mechanotransduction at the nuclear envelop:the role of forces in facilitating embryonic stem cell fate decision;Wylde;《Deposit and Copying of Dissertation Declaration》;20171020;第2.7节以及图5 * |
Also Published As
Publication number | Publication date |
---|---|
CN113652428A (zh) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2535365C2 (ru) | Способы получения и применения мультипотентных клеточных популяций | |
Shao et al. | Generation of iPS cells using defined factors linked via the self-cleaving 2A sequences in a single open reading frame | |
EP2669381A1 (en) | Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein | |
CN106636210B (zh) | 转录因子组合诱导成纤维细胞转分化为类睾丸间质细胞的方法 | |
JP2024511108A (ja) | 人工多能性幹細胞を取得するための方法 | |
Li et al. | MicroRNA-124 overexpression in schwann cells promotes schwann cell-astrocyte integration and inhibits glial scar formation ability | |
CN113652428B (zh) | 核膜蛋白敲降在干细胞移植方面的应用 | |
US20220298468A1 (en) | A method for developmentally activating a cell | |
US9163218B2 (en) | Method for increasing the efficiency of inducing pluripotent stem cells | |
KR102143320B1 (ko) | 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법 | |
CN116410934A (zh) | 制备ipsc并诱导其分化为目标体细胞的方法及用途 | |
WO2016076507A1 (ko) | 렙틴을 포함하는 유도만능줄기세포로의 역분화 유도용 조성물 및 이를 이용한 유도만능줄기세포로의 역분화 유도 방법 | |
CN114107253B (zh) | 一种利用工程细胞进行基因编辑的系统及方法 | |
LU500595B1 (en) | miR-16 and miR-30c joint Expression Vector, Construction Method and their Use | |
KR101269125B1 (ko) | 노치 신호 활성 유전자를 이용한 줄기세포의 증식 방법 | |
CN113166763B (zh) | 靶向cyp4v2基因突变位点的核酸分子及其用途 | |
CN103952406B (zh) | 抑制人恶性脑胶质瘤增殖的靶向STAT3基因的siRNA及其表达载体和应用 | |
KR102150489B1 (ko) | 소변세포로부터 신장전구세포로의 직접 역분화를 유도하는 방법 및 이의 방법으로 역분화된 신장전구세포를 포함하는 신장세포 손상 질환 예방 또는 치료용 약학 조성물 | |
CN112063656A (zh) | Map2k3或Map2k6在提高诱导成体细胞生成多能性干细胞效率中的用途 | |
CN116694630B (zh) | 一种促进环状rna过表达的序列组合及其应用 | |
CN113999816B (zh) | 一种表达hoxa10的人脐带间充质干细胞系及其制备方法和应用 | |
CN111808945B (zh) | Gabrd基因在筛选抗海洛因复吸药物中的应用 | |
CN116655774A (zh) | 过表达tlx的人诱导多能干细胞及其应用 | |
CN110857436B (zh) | 体外重编程制备视网膜节细胞的方法 | |
CN115960968A (zh) | 制备bcl11a红系增强子纯合突变的基因工程多能干细胞的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |